Vaccinex, Inc.
VCNXDrugs in Pipeline
11
Phase 3 Programs
3
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
How VCNX's past catalysts played out
Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine，Recombinant (Hansenula polymorpha)
Norovirus Infections
2 doses of vaccine Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha)
Human Papillomavirus (HPV) Infection
11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)
HPV InfectioN
VX15/2503
Huntington's Disease
Pepinemab
Alzheimer Disease
Avelumab and Pepinemab
Metastatic Pancreatic Adenocarcinoma
SARS-CoV-2 (LVRNA009) 50μg group
SARS-CoV-2
Biological/Vaccine: 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)
HPV Infection
low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)
COVID-19
VX15/2503 + avelumab
Carcinoma, Non-Small-Cell Lung
pepinemab + pembrolizumab
Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine，Recombinant (Hansenula polymorpha) | Phase 3 | Norovirus Infections | - | - |
2 doses of vaccine Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) | Phase 3 | Human Papillomavirus (HPV) Infection | - | - |
11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha) | Phase 3 | HPV InfectioN | - | - |
VX15/2503 | Phase 2 | Huntington's Disease | - | - |
Pepinemab | Phase 2 | Alzheimer Disease | - | - |
Avelumab and Pepinemab | Phase 2 | Metastatic Pancreatic Adenocarcinoma | - | - |
SARS-CoV-2 (LVRNA009) 50μg group | Phase 2 | SARS-CoV-2 | - | - |
Biological/Vaccine: 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha) | Phase 2 | HPV Infection | - | - |
low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell) | Phase 2 | COVID-19 | - | - |
VX15/2503 + avelumab | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
pepinemab + pembrolizumab | Phase 2 | Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC) | - | - |
Frequently asked questions
What is in Vaccinex, Inc.'s drug pipeline?→
CatalystAlert tracks 11 drug candidates in Vaccinex, Inc.'s (VCNX) pipeline across Phase 3, Phase 2. Its lead program is Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine，Recombinant (Hansenula polymorpha) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Vaccinex, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Vaccinex, Inc. (VCNX) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track VCNX biotech catalysts?→
Add VCNX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Vaccinex, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.